Europe Plasma Fractionation Market Share and Forecast by 2028

The plasma fractionation market in Europe is expected to grow from US$ 6,824.67 million in 2021 to US$ 10,402.95 million by 2028; it is estimated to grow at a CAGR of 6.2% from 2021 to 2028.

France, Germany, Italy, Spain, and the UK are major economies in Europe. the market offers considerable potential for the companies operating the market-related businesses. Due to the positive market growth, the Europe and regional market players are actively adopting organic and inorganic development strategies. Thus, it is expected to attract more significant investments in the market in the forecast period. For example, in August 2021, Biotest AG started about the sixth plasma collection center in the Czech Republic. The company received the operating license for these centers from the national public health authority SUKL. The center is state-of-the-art with about 15 donor beds and has facilities for the donors such as television, Wi-Fi, and others. The center is operational six days a week for twelve hours a day. Hence, fast market development owing to active participation of market players is the major factor driving the growth of the Europe plasma fractionation market.

In European countries, the medical practice of various chronic diseases such as neurological disorders, hematological disorders, and respiratory diseases has changed. Due to the diversification of the medical staff and the decision to focus on treating the critically ill, rising COVID-19 has impacted illness detection and treatment. Due to the current pandemic, many research organizations are focusing more on COVID-19 studies and are working hard to understand the virus better. Some of the federal agencies in the region have taken the initiative to adopt plasma therapy to treat COVID-19 patients. For instance, the National Agency for Medicines and Health Products Safety of France (ANSM) announced that immune plasma therapy would be used in treating critically ill patients. Also, the European Commission recommended the emergency use of convalescent plasma therapy to treat critical patients. Thus, the use of plasma therapies in the management of COVID-19 has positively impacted the market to some extent. However, due to COVID-19, the overall medical practice of neurological disorders, hematological disorders, and idiosyncratic disorders has changed, and the majority of pharmaceutical and biopharmaceutical companies are emphasizing on developing novel treatment therapies for COVID-19, which is negatively impacting the market growth.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe plasma fractionation market. The Europe plasma fractionation market is expected to grow at a good CAGR during the forecast period.

Europe Plasma FractionationMarket Revenue and Forecast to 2028 (US$ Million)

Europe Plasma Fractionation Market Segmentation

Europe Plasma Fractionation Market – By Product

• Immunoglobulin
  • Intravenous Immunoglobulin (IVIG)
  • Subcutaneous Immunoglobulin (SCIG)
  • Albumin
• Coagulation Factor Concentrates
• Protease Inhibitors
• Other

Europe Plasma Fractionation Market – By Application

• Neurology
• Immunology
• Hematology
• Critical Care
• Pulmonology
• Others

Europe Plasma Fractionation Market – By End User

• Hospitals and Clinics
• Clinical Research Laboratories
• Academic Institutes

Europe Plasma Fractionation Market, by Country

• France
• Germany
• Italy
• Spain
• UK
• Rest of Europe

Europe Plasma Fractionation Market - Companies Mentioned

• Bharat Serums and Vaccines Limited (BSV)
• Bio Products Laboratory Ltd.
• Biotest AG.
• CSL Limited
• Grifols, S.A.
• Kedrion S.p.A
• Octapharma AG
• Sanquin
• SK Plasma

Europe Plasma Fractionation Report Scope